Lupin Limited (LUPIN) - Total Assets
Based on the latest financial reports, Lupin Limited (LUPIN) holds total assets worth Rs335.00 Billion INR (≈ $3.62 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LUPIN net asset value for net asset value and shareholders' equity analysis.
Lupin Limited - Total Assets Trend (2004–2025)
This chart illustrates how Lupin Limited's total assets have evolved over time, based on quarterly financial data.
Lupin Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Lupin Limited's total assets of Rs335.00 Billion consist of 57.5% current assets and 42.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 5.3% |
| Accounts Receivable | Rs55.02 Billion | 18.8% |
| Inventory | Rs54.76 Billion | 18.8% |
| Property, Plant & Equipment | Rs55.04 Billion | 18.8% |
| Intangible Assets | Rs25.00 Billion | 8.6% |
| Goodwill | Rs22.33 Billion | 7.6% |
Asset Composition Trend (2004–2025)
This chart illustrates how Lupin Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lupin Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lupin Limited's current assets represent 57.5% of total assets in 2025, an increase from 56.0% in 2004.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, up from 2.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 18.8% of total assets.
Lupin Limited Competitors by Total Assets
Key competitors of Lupin Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Lupin Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 1.88 | 1.54 |
| Quick Ratio | 1.32 | 1.22 | 1.08 |
| Cash Ratio | 0.28 | 0.18 | 0.00 |
| Working Capital | Rs94.45 Billion | Rs70.30 Billion | Rs46.71 Billion |
Lupin Limited - Advanced Valuation Insights
This section examines the relationship between Lupin Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.15 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 21.7% |
| Total Assets | Rs292.05 Billion |
| Market Capitalization | $11.39 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Lupin Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lupin Limited's assets grew by 21.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lupin Limited (2004–2025)
The table below shows the annual total assets of Lupin Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs292.05 Billion ≈ $3.16 Billion |
+21.70% |
| 2024-03-31 | Rs239.97 Billion ≈ $2.60 Billion |
+4.54% |
| 2023-03-31 | Rs229.56 Billion ≈ $2.48 Billion |
+5.20% |
| 2022-03-31 | Rs218.21 Billion ≈ $2.36 Billion |
-7.58% |
| 2021-03-31 | Rs236.10 Billion ≈ $2.55 Billion |
-5.50% |
| 2020-03-31 | Rs249.84 Billion ≈ $2.70 Billion |
-10.61% |
| 2019-03-31 | Rs279.49 Billion ≈ $3.02 Billion |
+6.25% |
| 2018-03-31 | Rs263.05 Billion ≈ $2.84 Billion |
-1.13% |
| 2017-03-31 | Rs266.07 Billion ≈ $2.88 Billion |
+17.60% |
| 2016-03-31 | Rs226.25 Billion ≈ $2.45 Billion |
+72.21% |
| 2015-03-31 | Rs131.38 Billion ≈ $1.42 Billion |
+28.73% |
| 2014-03-31 | Rs102.06 Billion ≈ $1.10 Billion |
+14.50% |
| 2013-03-31 | Rs89.14 Billion ≈ $964.00 Million |
+11.67% |
| 2012-03-31 | Rs79.82 Billion ≈ $863.25 Million |
+30.34% |
| 2011-03-31 | Rs61.24 Billion ≈ $662.33 Million |
+20.43% |
| 2010-03-31 | Rs50.85 Billion ≈ $549.97 Million |
+23.01% |
| 2009-03-31 | Rs41.34 Billion ≈ $447.09 Million |
+22.90% |
| 2008-03-31 | Rs33.64 Billion ≈ $363.78 Million |
+48.64% |
| 2007-03-31 | Rs22.63 Billion ≈ $244.73 Million |
+12.71% |
| 2006-03-31 | Rs20.08 Billion ≈ $217.13 Million |
+48.25% |
| 2005-03-31 | Rs13.54 Billion ≈ $146.46 Million |
+10.10% |
| 2004-03-31 | Rs12.30 Billion ≈ $133.02 Million |
-- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more